RELIANCE: Moringa in Lactation and Early Childhood
1 other identifier
interventional
100
1 country
1
Brief Summary
This study will assess the impact of maternal moringa supplementation to mothers of breastfeeding infants on milk output, milk composition, exclusive breastfeeding duration, and maternal and child health. This will be accomplish by conducting a randomized, controlled dietary intervention study enrolling breastfeeding mothers and their newborn infants. Mothers will be randomized to receive either 10g dried moringa leaf powder in carrier vs. carrier alone, consumed daily for four months, with follow-up for 2 years. Women must be \>18 years of age, ≤ 30 days postpartum and exclusively breastfeeding at the time of enrollment. Infants must be at least 37 weeks of gestational age, be healthy and are able to feed orally and consume human milk. After randomization and enrollment, breast milk samples will be obtained at baseline, 2, 4, and 6 months. Serum from mothers will be collected at recruitment, 2, 6,and 9 months; infant serum will be collected by capillary sample at recruitment and approximately at 4, 6, 12, 18, and 24 months. Infant hemoglobin and infant feeding weights (test weights) will be collected on sequential days at recruitment, 4, and 6 months. 24-hour dietary recall: the foods and drinks consumed by mothers in the 24 hours prior to each milk sample. Other assessments will include perceptions of breastfeeding, assess complementary feeding practices. Review will be conducted of maternal and infant infections, diagnoses, and hospitalizations at the time of visit or since the last visit.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2026
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 14, 2026
CompletedFirst Posted
Study publicly available on registry
May 22, 2026
CompletedStudy Start
First participant enrolled
November 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2029
Study Completion
Last participant's last visit for all outcomes
June 1, 2030
May 22, 2026
May 1, 2026
2.8 years
May 14, 2026
May 19, 2026
Conditions
Outcome Measures
Primary Outcomes (3)
Maternal Serum Levels of Estradiol
Baseline, 2 months, 4 months, 6 months and 9 months
Maternal Serum Levels of Progesterone
Baseline, 2 months, 4 months, 6 months, and 9 months
Maternal Serum Levels of Prolactin
Baseline, 2 months, 4 months, 6 months, and 9 months
Study Arms (2)
Carrier and Moringa Leaf Powder
EXPERIMENTALCarrier
PLACEBO COMPARATORInterventions
Participants randomized to Moringa will consume 10 grams each day of the Moringa leaf powder mixed into porridge.
Eligibility Criteria
You may qualify if:
- Infants: must be born at term (=37-42 weeks), singleton birth, breastfeeding, age 7-21 days at enrollment
You may not qualify if:
- Mothers - women reporting regular consumption of moringa in the last month (\>1 time weekly), unable to consume moringa or unable to complete study activities within the first two weeks.
- Mothers - Women with a contraindication to Moringa use (blood thinners, levothyroxine, antihypertensive treatments, insulin dependency).
- Infants - significant congenital disease, are unable to feed orally.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Philip Kernlead
Study Sites (1)
SUNDY Downstate
Brooklyn, New York, 11203, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 14, 2026
First Posted
May 22, 2026
Study Start (Estimated)
November 1, 2026
Primary Completion (Estimated)
September 1, 2029
Study Completion (Estimated)
June 1, 2030
Last Updated
May 22, 2026
Record last verified: 2026-05